Characteristics of patients with NHL
| Characteristic . | No. (%) of patients (n = 79) . |
|---|---|
| Age, y | |
| Median (range) | 64 (30-82) |
| ≥60 | 51 (65) |
| Sex | |
| Male | 48 (61) |
| Female | 31 (39) |
| Ethnicity | |
| White | 71 (90) |
| Black or African American | 4 (5) |
| Asian | 2 (3) |
| American Indian/Alaskan Native | 1 (1) |
| ND | 1 (1) |
| Prior therapies | |
| All | 4 (1-12) |
| 1 | 2 (3) |
| 2-3 | 32 (41) |
| 4-6 | 30 (38) |
| ≥7 | 11 (14) |
| ND | 4 (5) |
| ECOG performance status | |
| 0 | 22 (28) |
| 1 | 55 (70) |
| 2 | 2 (3) |
| Disease stage | |
| II | 3 (4) |
| III | 14 (18) |
| IV | 49 (62) |
| ND | 13 (16) |
| International Prognostic Index | |
| Low risk (0-1) | 2 (3) |
| Low-intermediate risk (2) | 3 (4) |
| High-intermediate risk (3) | 31 (39) |
| High risk (4-5) | 27 (34) |
| ND | 16 (20) |
| Lactate dehydrogenase >ULN | 57 (72) |
| Nodal involvement | |
| ≤2 sites | 11 (14) |
| >2 sites | 62 (78) |
| ND | 6 (8) |
| NHL type | |
| DLBCL* | 43 (54) |
| FL | 9 (12) |
| RT | 8 (10) |
| CLL | 7 (9) |
| MCL | 4 (5) |
| CTCL | 3 (4) |
| PTCL | 3 (4) |
| Burkitt’s | 1 (1) |
| MZL | 1 (1) |
| Characteristic . | No. (%) of patients (n = 79) . |
|---|---|
| Age, y | |
| Median (range) | 64 (30-82) |
| ≥60 | 51 (65) |
| Sex | |
| Male | 48 (61) |
| Female | 31 (39) |
| Ethnicity | |
| White | 71 (90) |
| Black or African American | 4 (5) |
| Asian | 2 (3) |
| American Indian/Alaskan Native | 1 (1) |
| ND | 1 (1) |
| Prior therapies | |
| All | 4 (1-12) |
| 1 | 2 (3) |
| 2-3 | 32 (41) |
| 4-6 | 30 (38) |
| ≥7 | 11 (14) |
| ND | 4 (5) |
| ECOG performance status | |
| 0 | 22 (28) |
| 1 | 55 (70) |
| 2 | 2 (3) |
| Disease stage | |
| II | 3 (4) |
| III | 14 (18) |
| IV | 49 (62) |
| ND | 13 (16) |
| International Prognostic Index | |
| Low risk (0-1) | 2 (3) |
| Low-intermediate risk (2) | 3 (4) |
| High-intermediate risk (3) | 31 (39) |
| High risk (4-5) | 27 (34) |
| ND | 16 (20) |
| Lactate dehydrogenase >ULN | 57 (72) |
| Nodal involvement | |
| ≤2 sites | 11 (14) |
| >2 sites | 62 (78) |
| ND | 6 (8) |
| NHL type | |
| DLBCL* | 43 (54) |
| FL | 9 (12) |
| RT | 8 (10) |
| CLL | 7 (9) |
| MCL | 4 (5) |
| CTCL | 3 (4) |
| PTCL | 3 (4) |
| Burkitt’s | 1 (1) |
| MZL | 1 (1) |
CTCL, cutaneous T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; MZL, marginal zone lymphoma; ND, no data; PTCL, peripheral T-cell lymphoma; RT, Richter’s transformation.
Includes 1 patient with grade 3b FL.